Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Resultaten Admiral-studie: EMA-goedkeuring gilteritinib AML met FLT3-mutatie
dec 2019 | Leukemie